postpones dialysis, reduces blood pressure and saves billions to healthcare systems

The dialysis market is expected to reach 114 billion dollars in 2027 – a huge and expensive demand! Since dialysis in most countries is financed by govemental initiatives, the reduction in dialysis costs will reduce losses of hundreds of millions to healthcare organizations and free up budget for other diseases

The American National Institute of Health (NIH) recognized the importance of the project and funded its first study. The device is expected to significantly reduce the burden of dialysis patients on hospitals and save millions of people from early death

Curespec has succeeded in developing a groundbreaking and patent-protected device that treats chronic kidney disease and hypertension using shock waves

Over 700 million people suffer from CKD worldwide

10% of the world population!

Largest cause of death is currently Chronic Kidney Disease

Will become the 5th largets cause of death globally by 2040

Over 700 million people siffer from CKD worldwide

10% of the world population!

Largest cause of death is currently Chronic Kidney Disease

Will become the 5th largets cause of death globally by 2040

Unprecedented results in clinical trials:

A number of qualified investors have already joined this fundraising round. We invite you as well to read more about the company and join as investors and shareholders.

Want to speak with a Curespec manager? Send us your contact information and we’ll ensure a representative gets in contact with you.

Investment starting from (ILS) 75,000

About 10% of the world's population suffers from high blood pressure and kidney failure. This is a huge financial burden for medical insurance companies throughtout the world, and a cause of suffering for the general population. Curespe is expected to solve this growing problem, with an economical and easy-to-use solution.

This is why all the companies that have proven that they have a reasonable probability of being successful in the field, have been acquired or listed for hundreds of millions or billions of dollars. This is a very "thirsty" market with great potential.

Comparison between the revolutionary treatment of CURESPEC to dialysis:

Why invest in Curespec?:

Market Penetration

Curespec plans to enter the American and European markets which can quickly adopt the innovative treatment, and are in need of a solution to the problem of increasing sum costs of dialysis.

The plan is to receive reimbursement funding of at least $10,000 in the US and Europe per patient, which is 10% of the dialysis costs per year in these areas of the world. Curespec's solution is expected to postpone the need for dialysis and thus result in savings of up to 80% of the dialysis costs of these patients per year.

Business Model:

The company's business activities will be conducted in the following models:

1

B2B with hospitals, health funds and clinics.

2

Distribution agreements with leading companies in the field of medical devices.

3

B2D model in front of decision makers in health systems and insurance companies around the world, with the aim of integrating the treatment into the health care basket in Europe and obtaining approval for insurance indemnification in the United States.

System Purchase

A one time purchase of Nephrospec's ststem. With additional purchases of the consumable applications according to use and need.

PAY PER CLICK

system rental in a pay-per-use (PPC) model, meaning a fixed cost for each treatment that includes the depreciation of the machine and consumables.

Investment starting from (ILS) 75,000

Want to speak with a Curespec manager? Send us your contact information and we’ll ensure a representative gets in contact with you:

The problem and solution:

The kidneys play an important role in the the seperation of excess fluids and toxins from the blood and excreting them as urine. Their role is to maintain the balance of fluids and minerals in the body, regulating hormonal activity of the body's systems, influencing the structure of the skeleton, regulating and producing red blood cells, and regulating blood pressure. Any condition of reduced kidney function leads to chronic kidney disease (CKD), which may develop over time into end-stage renal disease (ESRD), a condition in which the kidneys do not function at all. These situations are called: renal failure or kidney failure. The two most common factors that contribute to the formation of kidney failure are diabetes and hypertension. About one third of diabetics will develop chronic kidney disease (CKD). High blood pressure significantly increases the risk of end-stage renal disease (ESRD). These factors are responsible for almost 75% of cases of kidney failure. Kidney failure is the tenth most common cause of death in the world and is expected to become the fifth most common cause of death by 2040.

The Generic Treatment:

Most of those suffering from kidney failure are treated with dialysis or undergo a kidney transplant to stay alive. The treatment for high blood pressure in most cases is done through drug prescription. Dialysis treatments are invasive and lead to high health costs, requiring lifelong treatment. The clinical results of this treatment are limited and indicate high rates of infections and a 5-year survival rate for 50% of the patients.

The revolutionalry treatment of Curespec:

Curespec's treatment system, Nephrospec™, ​​provides a breakthrough solution for the treatment of kidney failure and hypertension using low-intensity extracorporeal shock waves (Li-ESWT). It is a compact, portable system, easy to move, install and operate. No anesthesia or medication is needed. Nephrospec™ is a cost-effective, accessible treatment approach with proven effective results:

The adoption of the Nephrospec™ treatment by healthcare providers brings with it a tremendous economic value that will affect the health related expenses invested in patients with kidney failure. The savings can reach a reduction of about 80% of from expenses involved in providing dialysis treatments. The results of the studies conducted in Japan, the United States and Israel also indicate an overall reduction for treatment time due to the lack of need for hospitalization, and as a result of its proven effectiveness as a preventive treatment for target audiences with diabetes and hypertension who are at high risk of kidney failure. Thus, extending their lives and maintaining their life quality.

Reduces blood pressure. Lower by 20 mmHg

Delays the need of dialysis by at least 12 months

An improvement of 5% in kidney function

Cost savings of 80% over dialysis

 Nephrospec's treatment is intended for patients with stage 3-4 kidney failure, who are pre-dialysis and suffer from high blood pressure. Such patients currently exhibit no therapeutic response and their health condition continues to deteriorate to the point of needing dialysis.

Target Audience In The World

The Dialysis Market

Worldwide the dialysis market was estimated to stand at 82 billion dollars in 2020 with an expected market growth of 4.5% on average per year. The market is expected to reach 114 billion dollars a year by 2027. This is a huge burden on healthcare providers in developed countries. In the dialysis market there is a sub-market of products and consumables related to the dialysis procedure. According to the estimates, the aforementioned sub-market is also expected to grow by about 5% per year as a result of the growing demand for dialysis treatments.

Company Site Plans

In the European market, the company will expand its activities to multi-center research and will later start marketing the device for commercial professional use. The expectation is to start selling to customers about a year from now. After completing the process for FDA approval, the company will expand its operations in the United States and other markets around the world.

The Competition

As it currently stands, there are no companies on the market that offer the above-mentioned treatment. The efficiency offered by Curespec's system is unprecedented. There exists partial competition with technology for lowering blood pressure – RENAL DENERVATION, which works in a different way and offers treatment for hypertension without treating kidney failure. According to the company, Companies that produce devices and systems that incorporate shock wave technology will make efforts to enter the field in the future. Curespec's system is protected by a patent registered in the United States. This protection gives it a significant competitive advantage; precedence and firstness in entering the market. It should be noted that even if other devices are developed that use similar technology, it will take them time to get all the required approvals and will be limited by Curespec's patent, which was written in the maximum allowed detail.

Mapping Solutions Of Leading Companies In The Field

A comparison between Curespec and the other leading medical devices in the field:

Goals And Objectives

How will the investment be divided?

Investment starting from (ILS) 75,000

Want to speak with a Curespec manager? Send us your contact information and we’ll ensure a representative gets in contact with you:

Interested in participating in the trial?

Leave your contact info and we will get back to you:

Team

CEO

A Biomedical Engineer, 2005 Technion – Israel Institute of Technology. More than 15 years of experience in Medical Devices, leading teams of clinical applications, sales and product management.

Founder, Active Chairman, CTO

Has over 30 years experience in the international Medtech industry, having held top R&D management positions in medical instrument companies in Israel & the US. 

Clinical Director, Founding partner

Has 10 years of experience in the clinical diagnostics and medical device fields. Holds a doctorate in the fields of Molecular biology, biochemistry and microbiology from the Ben-Gurion-University of the Negev, Israel.

CFO

A Certified Public Accountant (CPA) from the Bar-Ilan University, and holds an MBA degree from the Hebrew University. Mr. Brandt has over 10 years of experience in financial management, including as a CFO in the private sector and as a Senior Auditor at Ernst & Young (EY).

R&D Director

An Electronics Engineer from HIT- Holon Institute of Technology. Expert in Product Development in all of its layers with wide knowledge in Shockwave systems and US imaging.

RA Manager

Has over 17 years of experience in the medical device industry as a Regulatory Affairs expert, developing regulatory strategies and compiling submissions to regulatory bodies worldwide.